文献速递认知障碍与痴呆

阿尔茨海默病患者的线粒体与糖酵解功能活体损伤

In vivo mitochondrial and glycolytic impairments in patients with Alzheimer disease.
PubMed 文献 · Neurology · 2020-03-05

本研究采用新型PET示踪剂[18F]BCPP-EF测量线粒体复合物I活性,并与[18F]FDG葡萄糖代谢对比,在32例AD患者及正常对照中评估脑内能量代谢。结果发现AD患者海马旁回的线粒体复合物I活性显著降低,而糖代谢未见显著下降,且早期AD除海马旁回外两示踪剂摄取呈正相关。

要点

  • AD患者海马旁回线粒体复合物I活性显著降低,提示氧化代谢衰竭。
  • 海马旁回葡萄糖代谢未见显著降低,线粒体功能障碍可能先于糖酵解减低。
  • 早期AD除海马旁回外,线粒体活性与糖代谢呈强正相关。

核心结论

  • 早期AD海马旁回存在线粒体功能障碍,线粒体相关能量衰竭可能先于糖酵解相关低代谢。

研究设计与样本

  • 首先在10名正常对照中量化[18F]BCPP-EF总分布容积,验证SUVRg可替代VT。
  • 18名正常对照接受[18F]BCPP-EF PET,另14名不同正常对照接受[18F]FDG PET。
  • 32例AD患者接受双示踪剂半定量PET扫描,进行个体间和个体内比较。

主要发现

  • AD患者海马旁回[18F]BCPP-EF SUVRg显著降低,而[18F]FDG SUVRg未见显著降低。
  • 早期AD除海马旁回外,多个脑区[18F]BCPP-EF SUVRg与[18F]FDG SUVRg呈强正相关。
  • [18F]BCPP-EF VT与SUVRg呈正相关,支持SUVRg用于半定量评估。

临床怎么用

  • 线粒体复合物I PET成像可早期识别AD海马旁回氧化代谢障碍。
  • 针对线粒体功能的干预可能早于糖代谢异常阶段。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: In vivo glycolysis-related glucose metabolism and electron transport chain-related mitochondrial activity may be different regionally in the brains of patients with Alzheimer disease (AD). To test this hypothesis regarding AD pathophysiology, we measured the availability of mitochondrial complex-I (MC-I) with the novel PET probe [18F]2-tert- butyl-4-chloro-5-2H- pyridazin-3-one ([18F]BCPP-EF), which binds to MC-I, and compared [18F]BCPP-EF uptake with 18F-fluorodeoxyglucose ([18F]FDG) uptake in the living AD brain. METHODS: First, the total distribution volume (VT) of [18F]BCPP-EF from 10 normal controls (NCs) was quantified using arterial blood samples and then tested to observe whether VT could substitute for the standard uptake value relative to the global count (SUVRg). Eighteen NCs and 14 different NCs underwent PET with [18F]BCPP-EF or [18F]FDG, respectively. Second, 32 patients with AD were scanned semiquantitatively with double PET tracers. Interparticipant and intraparticipant comparisons of the levels of MC-I activity ([18F]BCPP-EF) and glucose metabolism ([18F]FDG) were performed. RESULTS: The [18F]BCPP-EF VT was positively correlated with the [18F]BCPP-EF SUVRg, indicating that the use of the SUVRg was sufficient for semiquantitative evaluation. The [18F]BCPP-EF SUVRg, but not the [18F]FDG SUVRg, was significantly lower in the parahippocampus in patients with AD, highlighting the prominence of oxidative metabolic failure in the medial temporal cortex. Robust positive correlations between the [18F]BCPP-EF SUVRg and [18F]FDG SUVRg were observed in several brain regions, except the parahippocampus, in early-stage AD. CONCLUSIONS: Mitochondrial dysfunction in the parahippocampus was shown in early-stage AD. Mitochondria-related energy failure may precede glycolysis-related hypometabolism in regions with pathologically confirmed early neurodegeneration in AD.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Terada T, Obi T, Bunai T, et al. In vivo mitochondrial and glycolytic impairments in patients with Alzheimer disease. Neurology. 2020. PMID: 32139504. doi:10.1212/WNL.0000000000009249

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。